Jeff A. Wintersinger

Jeff A. Wintersinger

Auto-generated profile, based on publicly available information

Jeff A. Wintersinger

Department of Computer Science, University of Toronto, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Cell
Verified
Journal Article
Open access
SDStefan C. Dentro
Stefan C. Dentro
ILIgnaty Leshchiner
Ignaty Leshchiner
KHKerstin Haase
Kerstin Haase
MTMaxime Tarabichi
Maxime Tarabichi
JWJeff Wintersinger
Jeff Wintersinger
TYTsun-Po Yang
Tsun-Po Yang
Intra-tumor heterogeneity (ITH) is a mechanism of therapeutic resistance and therefore an important clinical challenge. However, the extent, origin, and drivers of ITH across cancer types are poorly understood. To address this, we extensively characterize ITH across whole-genome sequences of 2,658 cancer samples spanning 38 cancer types. Nearly all informative samples (95.1%) contain evidence of distinct subclonal expansions with frequent branching relationships between subclones. We observe positive selection of subclonal driver mutations across most cancer types and identify cancer type-specific subclonal patterns of driver gene mutations, fusions, structural variants, and copy number alterations as well as dynamic changes in mutational processes between subclonal expansions. Our results underline the importance of ITH and its drivers in tumor evolution and provide a pan-cancer resource of comprehensively annotated subclonal events from whole-genome sequencing data.

4 January 2021 in Nature Methods
Verified
Journal Article
Closed access
PDF file
MTMaxime Tarabichi
Maxime Tarabichi
ASAdriana Salcedo
Adriana Salcedo
ADAmit G. Deshwar
Amit G. Deshwar
MLMáire Ni Leathlobhair
Máire Ni Leathlobhair
JWJeff Wintersinger
Jeff Wintersinger
PBPaul C. Boutros
Paul C. Boutros

4 March 2022 in Blood Cancer Discovery
Verified
Journal Article
Open access
PDF file
JWJeff A. Wintersinger
Jeff A. Wintersinger
SDStephanie M. Dobson
Stephanie M. Dobson
EKEthan Kulman
Ethan Kulman
LSLincoln D. Stein
Lincoln D. Stein
JDJohn E. Dick
John E. Dick
QMQuaid Morris
Quaid Morris
Cancers are composed of genetically distinct subpopulations of malignant cells. DNA-sequencing data can be used to determine the somatic point mutations specific to each population and build clone trees describing the evolutionary relationships between them. These clone trees can reveal critical points in disease development and inform treatment. Pairtree is a new method that constructs more accurate and detailed clone trees than previously possible using variant allele frequency data from one or more bulk cancer samples. It does so by first building a Pairs Tensor that captures the evolutionary relationships between pairs of subpopulations, and then it uses these relations to constrain clone trees and infer violations of the infinite sites assumption. Pairtree can accurately build clone trees using up to 100 samples per cancer that contain 30 or more subclonal populations. On 14 B-progenitor acute lymphoblastic leukemias, Pairtree replicates or improves upon expert-derived clone tree reconstructions. Significance: Clone trees illustrate the evolutionary history of a cancer and can provide insights into how the disease changed through time (e.g., between diagnosis and relapse). Pairtree uses DNA-sequencing data from many samples of the same cancer to build more detailed and accurate clone trees than previously possible. See related commentary by Miller, p. 176. This article is highlighted in the In This Issue feature, p. 171.

11 July 2017 in bioRxiv
Verified
Preprint
Open access
PDF file
MGMoritz Gerstung
Moritz Gerstung
CJClemency Jolly
Clemency Jolly
ILIgnaty Leshchiner
Ignaty Leshchiner
SDStefan C. Dentro
Stefan C. Dentro
SGSantiago Gonzalez
Santiago Gonzalez
HGHeterogeneity Working Group
Heterogeneity Working Group
Summary: Cancer develops through a process of somatic evolution. Here, we use whole-genome sequencing of 2,778 tumour samples from 2,658 donors to reconstruct the life history, evolution of mutational processes, and driver mutation sequences of 39 cancer types. The early phases of oncogenesis are driven by point mutations in a small set of driver genes, often including biallelic inactivation of tumour suppressors. Early oncogenesis is also characterised by specific copy number gains, such as trisomy 7 in glioblastoma or isochromosome 17q in medulloblastoma. By contrast, increased genomic instability, a nearly four-fold diversification of driver genes, and an acceleration of point mutation processes are features of later stages. Copy-number alterations often occur in mitotic crises leading to simultaneous gains of multiple chromosomal segments. Timing analysis suggests that driver mutations often precede diagnosis by many years, and in some cases decades, providing a window of opportunity for early cancer detection.

5 May 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
SDStefan C. Dentro
Stefan C. Dentro
ILIgnaty Leshchiner
Ignaty Leshchiner
KHKerstin Haase
Kerstin Haase
MTMaxime Tarabichi
Maxime Tarabichi
JWJeff Wintersinger
Jeff Wintersinger
HCHeterogeneity Working Groupthe PCAWG consortium.
Heterogeneity Working Groupthe PCAWG consortium.
SUMMARY: Intra-tumor heterogeneity (ITH) is a mechanism of therapeutic resistance and therefore an important clinical challenge. However, the extent, origin and drivers of ITH across cancer types are poorly understood. To address this question, we extensively characterize ITH across whole-genome sequences of 2,658 cancer samples, spanning 38 cancer types. Nearly all informative samples (95.1%) contain evidence of distinct subclonal expansions, with frequent branching relationships between subclones. We observe positive selection of subclonal driver mutations across most cancer types, and identify cancer type specific subclonal patterns of driver gene mutations, fusions, structural variants and copy-number alterations, as well as dynamic changes in mutational processes between subclonal expansions. Our results underline the importance of ITH and its drivers in tumor evolution, and provide an unprecedented pan-cancer resource of comprehensively annotated subclonal events from whole-genome sequencing data.

19 January 2021 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
LSLinda K. Sundermann
Linda K. Sundermann
JWJeff Wintersinger
Jeff Wintersinger
GRGunnar Rätsch
Gunnar Rätsch
JSJens Stoye
Jens Stoye
QMQuaid Morris
Quaid Morris
Tumors contain multiple subpopulations of genetically distinct cancer cells. Reconstructing their evolutionary history can improve our understanding of how cancers develop and respond to treatment. Subclonal reconstruction methods cluster mutations into groups that co-occur within the same subpopulations, estimate the frequency of cells belonging to each subpopulation, and infer the ancestral relationships among the subpopulations by constructing a clone tree. However, often multiple clone trees are consistent with the data and current methods do not efficiently capture this uncertainty; nor can these methods scale to clone trees with a large number of subclonal populations. Here, we formalize the notion of a partially-defined clone tree (partial clone tree for short) that defines a subset of the pairwise ancestral relationships in a clone tree, thereby implicitly representing the set of all clone trees that have these defined pairwise relationships. Also, we introduce a special partial clone tree, the Maximally-Constrained Ancestral Reconstruction (MAR), which summarizes all clone trees fitting the input data equally well. Finally, we extend commonly used clone tree validity conditions to apply to partial clone trees and describe SubMARine, a polynomial-time algorithm producing the subMAR, which approximates the MAR and guarantees that its defined relationships are a subset of those present in the MAR. We also extend SubMARine to work with subclonal copy number aberrations and define equivalence constraints for this purpose. Further, we extend SubMARine to permit noise in the estimates of the subclonal frequencies while retaining its validity conditions and guarantees. In contrast to other clone tree reconstruction methods, SubMARine runs in time and space that scale polynomially in the number of subclones. We show through extensive noise-free simulation, a large lung cancer dataset and a prostate cancer dataset that the subMAR equals the MAR in all cases where only a single clone tree exists and that it is a perfect match to the MAR in most of the other cases. Notably, SubMARine runs in less than 70 seconds on a single thread with less than one Gb of memory on all datasets presented in this paper, including ones with 50 nodes in a clone tree. On the real-world data, SubMARine almost perfectly recovers the previously reported trees and identifies minor errors made in the expert-driven reconstructions of those trees. The freely-available open-source code implementing SubMARine can be downloaded at https://github.com/morrislab/submarine.